Andreas Pohlmann1, Babette Wagenhaus1, Thoralf Niendorf1, 2
1Berlin Ultrahigh Field Facility, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; 2Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charit Medical Faculty and the Max-Delbrck-Center, Berlin, Germany
Monitoring changes in blood volume with the use of intravascular contrast agents is of great interest for rodent studies of cerebrovascular diseases, fMRI and cerebrovascular reactivity. Ferumoxytol is a new intravenous iron preparation for treatment of the anemia of chronic kidney disease. It is a carbohydrate-coated USPIO and can also be used as a MRI contrast agent. In this study we investigated the use of ferumoxytol as a T2/T2* based MRI contrast reagent in rats at 9.4T. Its very slow wash-out and narrow, unvarying particle size distribution suggest that it may be well suited for rCBV quantification and rCBV-based fMRI.